Ezetimibe: cholesterol lowering and beyond

Expert Review of Cardiovascular Therapy
Harold E BaysAndrew M Tershakovec

Abstract

Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol. It appears to exert its effect by blocking intestinal sterol transporters, specifically Niemann-Pick C1-like 1 proteins, thereby inhibiting the intestinal absorption of cholesterol, phytosterols and certain oxysterols. Ezetimibe monotherapy and in combination with statin therapy is primarily indicated for lowering LDL-cholesterol levels. In addition, it may favorably affect other parameters that could potentially further reduce atherosclerotic coronary heart disease risk, such as raising HDL-cholesterol and lowering levels of triglycerides, non-HDL-cholesterol, apolipoprotein B and remnant-like particle cholesterol. Further effects of ezetimibe include a reduction in circulating phytosterols and oxysterols and, when used in combination with statins, a reduction in high-sensitivity C-reactive protein. The clinical significance of the LDL-cholesterol lowering and other effects of ezetimibe is being evaluated in clinical outcome studies.

References

Oct 16, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J S CohnJ Davignon
Jan 5, 2000·Physiological Reviews·G J Schroepfer
Mar 11, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·I StapransK R Feingold
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Nov 9, 2002·The American Journal of Cardiology·Carlos A DujovneUNKNOWN Ezetimibe Study Group
Nov 20, 2002·Expert Opinion on Investigational Drugs·Harold Bays
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 4, 2003·Journal of Lipid Research·Ilona StapransKenneth R Feingold
Apr 16, 2003·Kidney International. Supplement·Colin Baigent, Martin Landry
May 13, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Carlos Dujovne
May 30, 2003·Biochemical Society Transactions·G A HoldgateF McTaggart
Jul 4, 2003·Current Opinion in Lipidology·Stephen D Turley, John M Dietschy
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Evan A Stein
Nov 26, 2003·European Journal of Clinical Investigation·T A Miettinen, H Gylling
Dec 17, 2003·The American Journal of Cardiology·Philip T SagerUNKNOWN Ezetimibe Study Group
Jan 13, 2004·The American Journal of Cardiology·David D WatersUNKNOWN TNT Steering Committee Members and Investigators
Feb 11, 2004·Circulation·G SalenUNKNOWN Multicenter Sitosterolemia Study Group
Feb 21, 2004·Science·Scott W AltmannMichael P Graziano
Jun 15, 2004·The American Journal of Cardiology·Christie M BallantyneJoanne Palmisano
Aug 12, 2004·Biochemical and Biophysical Research Communications·Udo SeedorfGerd Assmann
Aug 24, 2004·Current Medicinal Chemistry. Cardiovascular and Hematological Agents·Lena NorménAtif B Awad
Oct 30, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Kenneth R WilundHelen H Hobbs
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv

❮ Previous
Next ❯

Citations

Mar 13, 2013·Drugs·Joe M ChehadeArshag D Mooradian
Sep 5, 2008·Current Opinion in Lipidology·Richard A Krasuski
Nov 22, 2011·Current Opinion in Lipidology·Harry R DavisThomas Musliner
Jan 6, 2011·Diabetes, Obesity & Metabolism·D S H BellJ H O'Keefe
Aug 21, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Stephen D TurleyJohn M Dietschy
Aug 23, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Mark A ValasekStephen D Turley
Dec 23, 2009·BMC Cell Biology·Ildikó KaszaLászló Homolya
Oct 24, 2012·Lipids in Health and Disease·Kirsi Laitinen, Helena Gylling
Dec 2, 2010·Lipids in Health and Disease·Harold BaysAndrew M Tershakovec
Jul 29, 2010·Lipids in Health and Disease·Carlo M RotellaGian Franco Gensini
Mar 23, 2011·Drug Metabolism and Drug Interactions·Fabiana D V GenvigirRosario D C Hirata
Sep 13, 2012·World Journal of Gastroenterology : WJG·José Antonio Del CampoManuel Romero-Gómez
Jul 5, 2012·World Journal of Hepatology·Laura TrapaniValentina Pallottini
Apr 23, 2011·Journal of Atherosclerosis and Thrombosis·Álvaro CerdaRosario Dominguez Crespo Hirata
Apr 7, 2016·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Harold BaysCraig Primack
Oct 28, 2008·Expert Opinion on Drug Metabolism & Toxicology·Irina A Pikuleva
Jun 23, 2012·Molecular and Cellular Endocrinology·Mariëtte Y M van der WulpAlbert K Groen
Apr 3, 2009·Mayo Clinic Proceedings·Firas J Al BadarinRandal J Thomas
Nov 26, 2008·Atherosclerosis·Manfredi RizzoKaspar Berneis
Oct 5, 2012·European Journal of Clinical Investigation·Hiroyuki TakaseGenjiro Kimura
Oct 13, 2011·IUBMB Life·Laura TrapaniValentina Pallottini
Mar 12, 2011·Fundamental & Clinical Pharmacology·Robert KrysiakBogusław Okopień
Apr 21, 2010·Translational Research : the Journal of Laboratory and Clinical Medicine·Todd C RideoutPeter J H Jones
Sep 13, 2016·ACS Infectious Diseases·Che C ColpittsThomas F Baumert
Apr 24, 2015·Cardiovascular Therapeutics·Alvaro CerdaRosario Dominguez Crespo Hirata
Oct 10, 2014·Atherosclerosis·Alberico L CatapanoAndrew M Tershakovec

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.